Karl Reinhard Aigner

from Wikipedia, the free encyclopedia

Karl Reinhard Aigner (born February 22, 1947 in Burghausen ) is a German vascular surgeon and oncologist .

Life

Aigner was born in Burghausen in 1947 and studied medicine in Erlangen . He then began his specialist training in cardiovascular surgery there and received his doctorate in 1973 on the subject of "Myocardial Revascularization". In 1977 he moved to the "Center for General and Thoracic Surgery" at the University of Gießen , where they were just about to introduce isolated perfusion in melanomas . This tumor therapy was developed in the 1950s by the German-born American Edward Krementz , but until then it could only be used for skin cancer . Aigner learned the process and researched a further implementation.

In 1981 he had developed a technique for performing the world's first isolated liver perfusion with a heart-lung machine on humans, which was presented in April 1982 at the international oncology congress. In the following years, a large number of surgical procedures and special catheters (e.g. the arterial port catheter) for the isolated therapy of organs and body parts, including pancreatic cancer , were added.

In 1982 Aigner initiated the international ICRCT congress series on regional chemotherapy. In 1984 he completed his habilitation at the "Center for General and Thoracic Surgery" in Gießen on techniques of regional chemotherapy and surgical oncology.

From 1986 to 1991 Aigner was chief physician for surgery at the Trostberg district hospital on Chiemsee, from 1992 to 2001 chief physician of the department for oncological surgery at the Asklepios Paulinen Klinik in Wiesbaden, from 2002 to 2005 head of the department for oncological surgery at Medias Klinik GmbH in Ransbach- Baumbach. Since 2006 he has been the medical director of Medias Klinikum GmbH & Co KG, private clinic for oncological surgery in Burghausen an der Salzach. Since 1994 he has been an associate professor at the Justus Liebig University in Giessen.

Cancer therapy

Aigner has been promoting regional chemotherapy (RCT) as a variant of oncological chemotherapy for treating tumors since the 1980s . In the professional world it is at best viewed as a special application for a small group of patients. Critics criticize the lack of scientific studies that prove the success. The German Cancer Research Center comes to the conclusion that the method is “only suitable for very few types of cancer and only in very specific situations”. Health insurance companies usually do not cover the costs.

criticism

Aigner was criticized in the media in April 2017 for dubious advertising methods. He had to admit that as an employee of the Medias Clinic he had paid a private advertising agency "a monthly flat fee " for advertising magazine articles under the guise of serious reporting. The agency had penned positive reports on alleged treatment successes, particularly the RCT, in tabloid media , although the treatment method is at least controversial.

Awards

  • AW Fischer Award, German Section of the International College of Surgeons, Berlin (1983)
  • Lions Award, Surgical Oncology, Paris (1988)
  • ET Krementz Award for Regional Chemotherapy, Rosenheim (1991)

literature

Web links

Individual evidence

  1. Fate turned . In: Der Spiegel . No. 17 , 1982, pp. 250-251 ( online ).
  2. Lifeless wrecks . In: Der Spiegel . No. 36 , 1985, pp. 197 ( online ).
  3. Christina Berndt: Clinic promotes cancer treatment - with dead patients. Süddeutsche Zeitung , April 18, 2017, accessed on April 18, 2017 .
  4. Peter Hornung, Djamila Benkhelouf: Cancer clinic advertises with dead. Norddeutscher Rundfunk , April 18, 2017, accessed on April 18, 2017 .
  5. Importance: What are the benefits of cytostatic treatment in cancer? krebsinformationsdienst.de of the DKFZ, accessed on April 18, 2017 .
  6. Christina Berndt: Clinic promotes cancer treatment - with dead patients. Süddeutsche Zeitung, April 18, 2017, accessed on April 18, 2017 .